{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:55:35Z","timestamp":1767851735328,"version":"3.49.0"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00c3\u00a8re des Affaires Sociales et de la Sant\u00c3\u00a9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejphar.2018.10.052","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T21:33:35Z","timestamp":1541194415000},"page":"66-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["New tricks for an old dog: A repurposing approach of apomorphine"],"prefix":"10.1016","volume":"843","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-4084","authenticated-orcid":false,"given":"Manon","family":"Auffret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Drapier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"V\u00e9rin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejphar.2018.10.052_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1464-410X.2008.07767.x","article-title":"Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction","volume":"102","author":"Afif-Abdo","year":"2008","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.ejphar.2018.10.052_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00002826-199510000-00005","article-title":"Acute challenge with apomorphine in Huntington's disease: a double-blind study","volume":"18","author":"Albanese","year":"1995","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1517\/14728214.2010.480973","article-title":"The future is today: emerging drugs for the treatment of erectile dysfunction","volume":"15","author":"Albersen","year":"2010","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000051001","article-title":"Oral treatment of erectile dysfunction with apomorphine SL","volume":"67","author":"Altwein","year":"2001","journal-title":"Urol. Int."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40268-018-0230-3","article-title":"The many faces of apomorphine: lessons from the past and challenges for the future","volume":"18","author":"Auffret","year":"2018","journal-title":"Drugs R&D"},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40261-018-0619-3","article-title":"Pharmacological insights into the use of apomorphine in Parkinson's disease: clinical relevance","volume":"38","author":"Auffret","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0028-3908(01)00178-2","article-title":"Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice","volume":"42","author":"Battaglia","year":"2002","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1743-6109.2004.04030.x","article-title":"A double blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine","volume":"1","author":"Bechara","year":"2004","journal-title":"J. Sex Med."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/sj.ijir.3900980","article-title":"Evidence for centrally initiated genital vasocongestive engorgement in the female rat: findings from a new model of female sexual arousal response","volume":"15","author":"Beharry","year":"2003","journal-title":"Int. J. Impot. Res."},{"issue":"Suppl.","key":"10.1016\/j.ejphar.2018.10.052_bib10","first-page":"180","article-title":"Apomorphine injections acutely improve chorea in patients with Huntington\u2019s disease","volume":"7","author":"Bentivoglio","year":"1992","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02226968","article-title":"Apomorphine in malignant syndrome due to levodopa withdrawal","volume":"13","author":"Bonuccelli","year":"1992","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2018.10.052_bib12","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","author":"Breckenridge","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejphar.2018.10.052_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1756285611411504","article-title":"Management of sexual dysfunction in Parkinson's disease","volume":"4","author":"Bronner","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.psychres.2011.09.022","article-title":"Sublingual apomorphine as a neuroendocrine probe","volume":"198","author":"Brunerova","year":"2012","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.fertnstert.2013.08.026","article-title":"Managing female sexual dysfunction","volume":"100","author":"Buster","year":"2013","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0014-2999(69)90093-4","article-title":"Effects of apomorphine, (+)-amphetamine, and nialamide on tetrabenazine-induced suppression of sexual behavior in the male rat","volume":"7","author":"Butcher","year":"1969","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib17","first-page":"155","article-title":"Effects of DA agonist in Huntington disease hyperkinesia","volume":"1","author":"Caraceni","year":"1980","journal-title":"Ital. J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2018.10.052_bib18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0090-4295(03)00694-0","article-title":"Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia: a prospective, open-label, pilot study","volume":"62","author":"Caruso","year":"2003","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ejphar.2018.10.052_bib19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.urology.2003.12.018","article-title":"Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder","volume":"63","author":"Caruso","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2018.10.052_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10641960600549827","article-title":"Protection by apomorphine in two independent models of acute inhibition of oxidative metabolism in rodents","volume":"28","author":"Castri","year":"2006","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.ejphar.2018.10.052_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/B978-0-444-63425-2.00010-6","article-title":"The role of dopamine in Huntington's disease","volume":"211","author":"Cepeda","year":"2014","journal-title":"Prog. Brain Res."},{"issue":"7","key":"10.1016\/j.ejphar.2018.10.052_bib22","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1177\/0963689717714105","article-title":"Impact of traumatic brain injury on dopaminergic transmission","volume":"26","author":"Chen","year":"2017","journal-title":"Cell Transplant."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-2999(01)01491-1","article-title":"Apomorphine, dopamine and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1","volume":"433","author":"Chiarenza","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00002826-199406000-00004","article-title":"Clinical usefulness of apomorphine in movement disorders","volume":"17","author":"Colosimo","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2018.10.052_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archneur.1978.00500250031006","article-title":"Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor","volume":"35","author":"Corsini","year":"1978","journal-title":"Arch. Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.ejphar.2018.10.052_bib27","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.ijir.3900993","article-title":"Multidimensional nature of apomorphine SL (Ixense) therapy","volume":"15","author":"Costa","year":"2003","journal-title":"Int. J. Impot. Res."},{"issue":"6","key":"10.1016\/j.ejphar.2018.10.052_bib28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.41.6.942","article-title":"Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction","volume":"41","author":"Cunningham","year":"1991","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.ijir.3901293","article-title":"Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips","volume":"17","author":"d'Emmanuele di Villa Bianca","year":"2005","journal-title":"Int. J. Impot. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib30","first-page":"73","article-title":"A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening","volume":"7","author":"Da Costa","year":"2014","journal-title":"Dis. Model. Mech."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003495-200363020-00003","article-title":"Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies","volume":"63","author":"DasGupta","year":"2003","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0006-2952(00)00524-4","article-title":"Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants","volume":"61","author":"dos Santos El-Bach\u00e1","year":"2001","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2018.10.052_bib33","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ageing\/afl096","article-title":"It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease","volume":"35","author":"Douglas","year":"2006","journal-title":"Age Ageing."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000126346","article-title":"Apoptosis in the anterior pituitary gland of the rat: studies with estrogen and bromocriptine","volume":"57","author":"Drewett","year":"1993","journal-title":"Neuroendocrinology."},{"key":"10.1016\/j.ejphar.2018.10.052_bib35","unstructured":"European Medicine Agency (EMA). EU\/3\/12\/954. Public summary of opinion on orphan designation: S[+] apomorphine for the treatment of amyotrophic lateral sclerosis. \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/orphans\/2012\/03\/human_orphan_001028.jsp&mid=WC0b01ac058001d12b\u3009."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1756285610375328","article-title":"Multiple system atrophy: current and future approaches to management","volume":"3","author":"Flabeau","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0031-9384(79)90088-X","article-title":"Role of hypothalamic dopaminergic receptors in the control of lordosis behavior in the female rat","volume":"22","author":"Foreman","year":"1979","journal-title":"Physiol. Behav."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/02699050802649662","article-title":"Fast awakening from minimally conscious state with apomorphine","volume":"23","author":"Fridman","year":"2009","journal-title":"Brain Inj."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib39","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3109\/02699051003610433","article-title":"Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury","volume":"24","author":"Fridman","year":"2010","journal-title":"Brain Inj."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.58.2.241","article-title":"Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy","volume":"58","author":"Friess","year":"2001","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF03324659","article-title":"Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine","volume":"18","author":"Gambassi","year":"2006","journal-title":"Aging Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-2999(96)00291-9","article-title":"Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction","volume":"308","author":"Gassen","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib43","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mds.870130409","article-title":"Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine","volume":"13","author":"Gassen","year":"1998","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.ejphar.2018.10.052_bib44","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00702-014-1232-0","article-title":"Restless legs syndrome in multiple system atrophy","volume":"121","author":"Ghorayeb","year":"2014","journal-title":"J. Neural. Transm."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2018.10.052_bib45","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/sj.ijir.3900806","article-title":"Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug","volume":"14","author":"Giuliano","year":"2002","journal-title":"Int. J. Impot. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0026-895X(25)14947-X","article-title":"Aporphine enantiomers. Interactions with D-1 and D-2 dopamine receptors","volume":"25","author":"Goldman","year":"1984","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.10.052_bib47","unstructured":"Graham, M.D., Pfaus, J., 2008. Infusion of the dopamine agonist apomorphine to the medial preoptic are facilitates appetitive sexual behaviours of female rats. Abstract B-E2160, 2nd Annual Canadian Neuroscience Meeting (Canadian Association for Neuroscience), May 25\u201328, 2008, Montreal, Canada. \u3008https:\/\/www.can-acn.org\/meeting2008\/abstracts\/416.htm\u3009."},{"key":"10.1016\/j.ejphar.2018.10.052_bib48","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/1531-8257(199907)14:4<612::AID-MDS1010>3.0.CO;2-6","article-title":"Apomorphine protects against MPTP-induced neurotoxicity in mice","volume":"14","author":"Gr\u00fcnblatt","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2018.10.052_bib49","first-page":"57","article-title":"Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity","volume":"55","author":"Gr\u00fcnblatt","year":"1999","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejphar.2018.10.052_bib50","first-page":"146","article-title":"Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss","volume":"77","author":"Gr\u00fcnblatt","year":"2001","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/1355621021000006206","article-title":"The apomorphine test: a biological marker for heroin dependence disorder?","volume":"7","author":"Guardia","year":"2002","journal-title":"Addict. Biol."},{"issue":"10","key":"10.1016\/j.ejphar.2018.10.052_bib52","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1046\/j.1460-9568.2002.02256.x","article-title":"Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures","volume":"16","author":"Guo","year":"2002","journal-title":"Eur. J. Neurosci."},{"issue":"8","key":"10.1016\/j.ejphar.2018.10.052_bib53","first-page":"37","article-title":"Effects of apomorphine and haloperidol on experimental hepatocarcinogenesis","volume":"29","author":"Gurkalo","year":"1983","journal-title":"Vopr Onkol."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0987-7053(03)00056-X","article-title":"Acute low single dose of apomorphine reduces periodic limb movements but has no significant effect on sleep arousals: a preliminary report","volume":"33","author":"Haba-Rubio","year":"2003","journal-title":"Neurophysiol. Clin."},{"issue":"02","key":"10.1016\/j.ejphar.2018.10.052_bib55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0014-2999(75)90304-0","article-title":"Apomorphine: facilitation of sexual behaviour in female rats","volume":"32","author":"Hamburger-Bar","year":"1975","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejphar.2018.10.052_bib56","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.bmc.2018.01.028","article-title":"Mechanistic analyses of the suppression of amyloid \u03b242 aggregation by apomorphine","volume":"26","author":"Hanaki","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ghir.2007.04.002","article-title":"Growth hormone response to low-dose apomorphine in restless legs syndrome","volume":"17","author":"Happe","year":"2007","journal-title":"Growth Horm. IGF Res."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib58","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/jnr.20974","article-title":"Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway","volume":"84","author":"Hara","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2018.10.052_bib59","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"8","key":"10.1016\/j.ejphar.2018.10.052_bib60","doi-asserted-by":"crossref","first-page":"e105041","DOI":"10.1371\/journal.pone.0105041","article-title":"EEG source connectivity analysis: from dense array recordings to brain networks","volume":"9","author":"Hassan","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejphar.2018.10.052_bib61","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0022-5347(17)38543-9","article-title":"The characterization of a bio-assay of erectile function in a rat model","volume":"145","author":"Heaton","year":"1991","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib62","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)35090-5","article-title":"Effects of castration and exogenous testosterone supplementation in an animal model of penile erection","volume":"151","author":"Heaton","year":"1994","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib63","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0090-4295(95)80005-0","article-title":"Recovery of erectile function by the oral administration of apomorphine","volume":"45","author":"Heaton","year":"1995","journal-title":"Urology"},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2018.10.052_bib64","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1038\/sj.ijir.3900721","article-title":"Characterising the benefit of apomorphine SL (Uprima) as an optimised treatment for representative populations with erectile dysfunction","volume":"13","author":"Heaton","year":"2001","journal-title":"Int. J. Impot. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.ijir.3900831","article-title":"Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction","volume":"14","author":"Heaton","year":"2002","journal-title":"Int. J. Impot. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib66","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.22319","article-title":"Apomorphine treatment in Alzheimer mice promoting amyloid-\u03b2 degradation","volume":"69","author":"Himeno","year":"2011","journal-title":"Ann. Neurol."},{"issue":"40","key":"10.1016\/j.ejphar.2018.10.052_bib67","doi-asserted-by":"crossref","first-page":"405101","DOI":"10.1088\/0957-4484\/21\/40\/405101","article-title":"Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug","volume":"21","author":"Hsu","year":"2010","journal-title":"Nanotechnology"},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1439-0272.2008.00860.x","article-title":"Effect of sublingual medication of sildenafil citrate\/ apomorphine on sexual behaviour of male rats","volume":"41","author":"Huang","year":"2009","journal-title":"Andrologia"},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2018.10.052_bib69","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S1353-8020(02)00123-2","article-title":"Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group","volume":"9","author":"Ikebe","year":"2003","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"10.1016\/j.ejphar.2018.10.052_bib70","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.6b01027","article-title":"Lipid-drug conjugate for enhancing drug delivery","volume":"14","author":"Irby","year":"2017","journal-title":"Mol. Pharm."},{"issue":"11","key":"10.1016\/j.ejphar.2018.10.052_bib71","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.bmcl.2017.03.082","article-title":"Investigation of the inhibitory mechanism of apomorphine against MDM2-p53 interaction","volume":"27","author":"Ishiba","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.ijir.3900844","article-title":"Effect of apomorphine on intracavernous pressure and blood pressure in conscious, spinalized rats","volume":"14","author":"Ishizuka","year":"2002","journal-title":"Int. J. Impot. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib73","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.bbrc.2017.04.151","article-title":"Apomorphine suppresses TNF-\u03b1-induced MMP-9 expression and cell invasion through inhibition of ERK\/AP-1 signaling pathway in MCF-7 cells","volume":"487","author":"Jung","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2018.10.052_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/mds.27363","article-title":"Huntington's disease: current and future therapeutic prospects","author":"Kieburtz","year":"2018","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.ejphar.2018.10.052_bib75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1248\/bpb1978.13.426","article-title":"Suppression of tumor cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine, and apomorphine","volume":"13","author":"Kondo","year":"1990","journal-title":"J. Pharmacobiodyn."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/109454503765361551","article-title":"Neuroprotective, anti-apoptotic effects of apomorphine","volume":"6","author":"Kyriazis","year":"2003","journal-title":"J. Anti Aging Med."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib77","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.ijir.3900816","volume":"14","author":"Lammers","year":"2002","journal-title":"Int. J. Impot. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib78","first-page":"113","article-title":"Apomorphine, pimozide, L-Dopa and the probenecid test in Huntington's chorea","volume":"76","author":"Lal","year":"1973","journal-title":"Psychiatr. Neurol. Neurochir."},{"key":"10.1016\/j.ejphar.2018.10.052_bib79","first-page":"722","article-title":"Apomorphine and psychopathology","volume":"38","author":"Lal","year":"1975","journal-title":"JNNP"},{"issue":"3-4","key":"10.1016\/j.ejphar.2018.10.052_bib80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0278-5846(89)90122-X","article-title":"Apomorphine: clinical studies on erectile impotence and yawning","volume":"13","author":"Lal","year":"1989","journal-title":"Prog Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"45","key":"10.1016\/j.ejphar.2018.10.052_bib81","doi-asserted-by":"crossref","first-page":"42881","DOI":"10.1074\/jbc.M206593200","article-title":"New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease","volume":"277","author":"Lashuel","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ejphar.2018.10.052_bib82","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1176\/ajp.2006.163.8.1450","article-title":"Subcutaneous apomorphine for neuroleptic malignant syndrome","volume":"163","author":"Lattanzi","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib83","doi-asserted-by":"crossref","first-page":"e0150460","DOI":"10.1371\/journal.pone.0150460","article-title":"Drug repositioning for cancer therapy based on large-scale drug-induced transcriptional signatures","volume":"11","author":"Lee","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ejphar.2018.10.052_bib84","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1096\/fj.05-5510fje","article-title":"Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons","volume":"20","author":"Li","year":"2006","journal-title":"FASEB J."},{"issue":"1-2","key":"10.1016\/j.ejphar.2018.10.052_bib85","first-page":"50","article-title":"Psychooncology and cancer progression-related alterations of pleasure-associated neurochemical system: Abnormal neuroendocrine response to apomorphine in advanced cancer patients","volume":"24","author":"Lissoni","year":"2003","journal-title":"Neuro Endocrinol. Lett."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib86","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3233\/JAD-2011-110140","article-title":"Activation of glutathione peroxidase and inhibition of p53-related apoptosis by apomorphine","volume":"27","author":"Ma","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib87","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1464-410X.2006.06253.x","article-title":"Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction","volume":"98","author":"Maclennan","year":"2006","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib88","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF03033258","article-title":"Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells","volume":"1","author":"Maggio","year":"2000","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ejphar.2018.10.052_bib89","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF03033258","article-title":"Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells","volume":"1","author":"Maggio","year":"1999","journal-title":"Neurotox. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib90","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1677\/joe.0.0730187","article-title":"Dopaminergic reversal of the decline after castration of rat copulatory behaviour","volume":"73","author":"Malmn\u00e4s","year":"1977","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejphar.2018.10.052_bib91","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1385\/JMN:24:3:401","article-title":"Iron and a-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin- 3-gallate","volume":"24","author":"Mandel","year":"2004","journal-title":"J. Mol. Neurosci."},{"issue":"21","key":"10.1016\/j.ejphar.2018.10.052_bib92","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1212\/WNL.0000000000005573","article-title":"Anatomo-functional basis of restless legs syndrome","volume":"90","author":"Mano","year":"2018","journal-title":"Neurology"},{"issue":"Pt 2","key":"10.1016\/j.ejphar.2018.10.052_bib93","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/brain\/124.2.331","article-title":"Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations","volume":"124","author":"Manson","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2018.10.052_bib94","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib95","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjp.0706317","article-title":"Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum","volume":"146","author":"Matsumoto","year":"2005","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2018.10.052_bib97","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.freeradbiomed.2013.04.018","article-title":"S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis","volume":"61","author":"Mead","year":"2013","journal-title":"Free Radic Biol. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijep.2016.09.002","article-title":"Drug repositioning","volume":"3","author":"Mehndiratta","year":"2016","journal-title":"Int. J. Epilepsy"},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib99","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0006-8993(87)90272-1","article-title":"Apomorphine-induced penile erection and yawning: site of action in brain","volume":"415","author":"Melis","year":"1987","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000126677","article-title":"Apomorphine-and oxytocin-induced penile erection and yawning in intact and castrated male rats: effect of sexual steroids","volume":"59","author":"Melis","year":"1994","journal-title":"Neuroendocrinology"},{"issue":"36","key":"10.1016\/j.ejphar.2018.10.052_bib101","doi-asserted-by":"crossref","first-page":"13485","DOI":"10.1073\/pnas.0605993103","article-title":"Dopamine targets cycling B cells independent of receptors\/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma","volume":"103","author":"Meredith","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.ejphar.2018.10.052_bib102","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1517\/17425255.2012.727797","article-title":"The evaluation of apomorphine for the treatment of erectile dysfunction","volume":"8","author":"Mohee","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib103","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.ijir.3900999","article-title":"Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction","volume":"15","author":"Montorsi","year":"2003","journal-title":"Int. J. Impot. Res."},{"issue":"Suppl 2","key":"10.1016\/j.ejphar.2018.10.052_bib104","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.ijir.3900991","article-title":"Tolerability and safety of apomorphine SL (Ixense (TM))","volume":"15","author":"Montorsi","year":"2003","journal-title":"Int. J. Impot. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2018.10.052_bib105","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/sj.ijir.3900720","article-title":"Apomorphine to Uprima: the development of a practical erectogenic drug: a personal perspective","volume":"13","author":"Morales","year":"2001","journal-title":"Int. J. Impot. Res."},{"key":"10.1016\/j.ejphar.2018.10.052_bib106","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mdc3.12039","article-title":"Continuous subcutaneous apomorphine infusion improves severe restless legs syndrome","volume":"1","author":"M\u00fcller","year":"2014","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.ejphar.2018.10.052_bib107","article-title":"Aporphines and Alzheimer's disease: towards a medical approach facing the future","author":"Nabavi","year":"2018","journal-title":"Curr Med Chem."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib108","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3233\/JAD-160344","article-title":"Apomorphine therapy for neuronal insulin resistance in a mouse model of alzheimer's disease","volume":"58","author":"Nakamura","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib109","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH consensus development panel on impotence","volume":"270","author":"NIH Consensus Conference","year":"1993","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mds.870130326","article-title":"Apomorphine-induced penile erections in Parkinson's disease","volume":"13","author":"O'Sullivan","year":"1998","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib111","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/bbrc.2000.2732","article-title":"Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes","volume":"272","author":"Ohta","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2018.10.052_bib112","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.4172\/2161-0460.1000e122","article-title":"Apomorphine: a novel efficacy for alzheimer\u2019s disease and its mechanisms","volume":"2","author":"Ohyagi","year":"2012","journal-title":"J. Alzheimers Dis. Parkinsonism"},{"key":"10.1016\/j.ejphar.2018.10.052_bib113","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/NDT.S118438","article-title":"Neuroleptic malignant syndrome: an easily overlooked neurologic emergency","volume":"13","author":"Oruch","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib114","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/mds.1254","article-title":"Effects of apomorphine on flexor reflex and periodic limb movement","volume":"17","author":"Paradiso","year":"2002","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib115","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0028-3908(03)00152-7","article-title":"Dose-dependent induction of apoptosis by R-apomorphine in CHO-K1 cell line in culture","volume":"45","author":"Pardini","year":"2003","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib116","first-page":"205","article-title":"Potentiation of apomorphine effect on sildenafil-induced penile erection in conscious rabbits","volume":"6","author":"Park","year":"2004","journal-title":"Asian J. Androl."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib117","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/BF00445548","article-title":"The effects of intrathecal administration of the dopamine agonist apomorphine on penile reflexes and copulation in the male rat","volume":"99","author":"Pehek","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.10.052_bib118","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mdc3.12145","article-title":"Current concepts in the treatment of multiple system atrophy","volume":"2","author":"Perez\u2010Lloret","year":"2015","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib119","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1439-0272.2004.00614.x","article-title":"Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study","volume":"36","author":"Perimenis","year":"2004","journal-title":"Andrologia"},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1590\/S0100-879X2005000400001","article-title":"Genotoxic, neurotoxic and neuroprotective activities of apomorphine and its oxidized derivative 8-oxo-apomorphine","volume":"38","author":"Picada","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib121","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbrc.2018.03.001","article-title":"Reprint of: a chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth","volume":"499","author":"Pinheiro","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.ejphar.2018.10.052_bib122","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/11535940-000000000-00000","article-title":"Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs?","volume":"24","author":"Pistoia","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib123","first-page":"61","article-title":"Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction\u2013an open, randomized cross-over study with flexible dosing","volume":"12","author":"Porst","year":"2007","journal-title":"Eur. J. Med. Res."},{"issue":"9208","key":"10.1016\/j.ejphar.2018.10.052_bib124","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0140-6736(05)74775-9","article-title":"The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)","volume":"355","author":"Raju","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0404.1999.tb00732.x","article-title":"Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome","volume":"100","author":"Reuter","year":"1999","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.ejphar.2018.10.052_bib126","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.3390\/molecules17055289","article-title":"The pharmacological properties and therapeutic use of apomorphine","volume":"17","author":"Ribari\u010d","year":"2012","journal-title":"Molecules"},{"issue":"4 Pt 1","key":"10.1016\/j.ejphar.2018.10.052_bib127","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/j.1743-6109.2009.01540.x","article-title":"Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings","volume":"7","author":"Riley","year":"2010","journal-title":"J. Sex Med."},{"issue":"2-3","key":"10.1016\/j.ejphar.2018.10.052_bib128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02251227","article-title":"Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism","volume":"10","author":"Sam","year":"1995","journal-title":"J. Neural Transm. Park Dis. Dement. Sect."},{"issue":"6","key":"10.1016\/j.ejphar.2018.10.052_bib129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/archneur.1979.00500420059006","article-title":"Sedative effects of apomorphine in an animal model of Huntington's disease","volume":"36","author":"Sanberg","year":"1979","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0091-3057(90)90015-A","article-title":"Systemic or intracranial apomorphine increases copulation in long-term castrated male rats","volume":"37","author":"Scaletta","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2018.10.052_bib131","first-page":"47","article-title":"Apomorphine has a potent antiproliferative effect on Chinese hamster ovary cells","volume":"55","author":"Scarselli","year":"1999","journal-title":"J. Neural. Transm."},{"issue":"6","key":"10.1016\/j.ejphar.2018.10.052_bib132","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1210\/jcem-71-6-1669","article-title":"Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors","volume":"71","author":"Schrell","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib133","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1124\/mol.112.081976","article-title":"Apomorphine is a bimodal modulator of TRPA1 channels","volume":"83","author":"Schulze","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib134","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14737175.2015.1025383","article-title":"Dopamine and Huntington's disease","volume":"15","author":"Schwab","year":"2015","journal-title":"Expert Rev. Neurother."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/(SICI)1099-0844(199709)15:3<191::AID-CBF738>3.0.CO;2-2","article-title":"Apomorphine inhibits the growth-stimulating effect of retinal pigment epithelium on scleral cells in vitro","volume":"15","author":"Seko","year":"1997","journal-title":"Cell Biochem. Funct."},{"issue":"17","key":"10.1016\/j.ejphar.2018.10.052_bib136","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/0008-5472.CAN-18-1022","article-title":"Therapeutic targeting of the premetastatic stage in human lung-to-brain metastasis","volume":"78","author":"Singh","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.10.052_bib137","doi-asserted-by":"crossref","unstructured":"Solayman, M.H., Badary, O.A., Salem, K.A., El-Hamamsy, 2012. PIH4 Is Sildenafil \u2013 Apomorphine Sublingual Combination Significantly More Effective than Sublingual Sildenafil in Treating Erectile Dysfunction? Value in Health, 15(4), A192.","DOI":"10.1016\/j.jval.2012.03.1036"},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib138","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ana.22359","article-title":"Apomorphine and Alzheimer A \u03b2: roles for regulated \u03b1 cleavage, autophagy, and antioxidation?","volume":"69","author":"Steele","year":"2011","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib139","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1464-410X.2004.04565.x","article-title":"Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury","volume":"93","author":"Strebel","year":"2004","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib140","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF01921676","article-title":"Aphrodisiac effect of L-DOPA and apomorphine in male sexually sluggish rats","volume":"30","author":"Tagliamonte","year":"1974","journal-title":"Experientia"},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib141","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/sj.ijir.3900552","article-title":"Systemic administration of apomorphine improves the hemodynamic mechanism of clitoral and vaginal engorgement in the rabbit","volume":"12","author":"Tarcan","year":"2000","journal-title":"Int. J. Impot. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib142","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbrc.2013.06.110","article-title":"Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors","volume":"438","author":"Thomas","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.ejphar.2018.10.052_bib143","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/0024-3205(74)90319-1","article-title":"Apomorphine in Huntington's chorea: clinical observations and theoretical considerations","volume":"15","author":"Tolosa","year":"1974","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2018.10.052_bib144","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00415-005-0636-z","article-title":"Treatment of restless legs syndrome with subcutaneous apomorphine in a patient with short bowel syndrome","volume":"252","author":"Tings","year":"2005","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.2003.034843","article-title":"Apomorphine in idiopathic restless legs syndrome: an exploratory study","volume":"76","author":"Tribl","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejphar.2018.10.052_bib146","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0891-5849(93)90055-Y","article-title":"Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines","volume":"15","author":"Ubeda","year":"1993","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib147","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0197-4580(92)90026-T","article-title":"Age-related changes in apomorphine-induced erections","volume":"13","author":"Varrin","year":"1992","journal-title":"Neurobiol. Aging"},{"issue":"16","key":"10.1016\/j.ejphar.2018.10.052_bib148","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/mds.21718","article-title":"Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: a double blind, randomized cross-over trial","volume":"22","author":"Vitale","year":"2007","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.ejphar.2018.10.052_bib149","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrneurol.2017.147","article-title":"A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.ejphar.2018.10.052_bib150","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/mds.1133","article-title":"Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy","volume":"16","author":"Wang","year":"2001","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.ejphar.2018.10.052_bib151","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-2006-957749","article-title":"Inhibition of eukaryote protein kinases by isoquinoline and oxazine alkaloids","volume":"63","author":"Wang","year":"1997","journal-title":"Planta Med."},{"key":"10.1016\/j.ejphar.2018.10.052_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/mds.27260","article-title":"Treatment of restless legs syndrome: evidence-based review and implications for clinical practice (Revised 2017)","author":"Winkelmann","year":"2018","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.ejphar.2018.10.052_bib153","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.26422","article-title":"Apomorphine: a potential modifier of amyloid deposition in Parkinson's disease?","volume":"31","author":"Yarnall","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2018.10.052_bib154","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.1999.tb07977.x","article-title":"The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators","volume":"890","author":"Youdim","year":"1999","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2018.10.052_bib155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainres.2004.08.015","article-title":"Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease","volume":"1026","author":"Yuan","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.10.052_bib156","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fnmol.2017.00231","article-title":"Cell death-autophagy loop and glutamate-glutamine cycle in amyotrophic lateral sclerosis","volume":"10","author":"Yuan","year":"2017","journal-title":"Front. Mol. Neurosci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918306423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918306423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:24:57Z","timestamp":1757975097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918306423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":156,"alternative-id":["S0014299918306423"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.10.052","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New tricks for an old dog: A repurposing approach of apomorphine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.10.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}